Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study.-Reference-Cited by-同舟云学术

Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study.

Published:2023-11 Issue: Volume: Page:
ISSN:2287-8882
Container-title:Prostate International
language:en
Short-container-title:Prostate International

Author:

López-Abad Alicia^ORCID,Ramírez Backhaus Miguel,Server Gómez Gerardo,Cao Avellaneda Enrique,Moreno Alarcón Cristóbal,López Cubillana Pedro,Yago Giménez Pablo,de Pablos Rodríguez Pedro^ORCID,Juan Fita María J.,Climent Durán Miguel Á.,Guardiola Ruiz Iris,Vidal Crespo Natalia,Artés Artés Miriam^ORCID,Montoya Chinchilla Raúl,Moreno Avilés Juan,Guzmán Martínez-Valls Pablo L.^ORCID,López González Pedro Á.

Publisher

Elsevier BV

Subject

Urology

Reference35 articles.

1. World Health Organization,2022

2. Las cifras del cáncer en España,2021

3. Registro nacional de cáncer de próstata 2010 en España;Cózar;Actas Urol Esp,2013

4. Who dies from prostate cancer?;Patrikidou;Prostate Cancer Prostatic Dis,2014

5. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019);James;Eur Urol,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring novel Apalutamide analogues as potential therapeutics for prostate cancer: design, molecular docking investigations and molecular dynamics simulation;Frontiers in Chemistry;2024-08-06

2. Does androgenic alopecia aggravate the risk of prostate cancer? Evidence from Mendelian randomization;Prostate International;2024-06